Trgovina Eli Lilly & Co - LLY CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | 1.11 | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.030779% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | -0.013666% | ||||||||
Čas nočne pristojbine | 22:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Eli Lilly and Co ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Predhodno. Zapri* | 337.93 |
Odpri* | 340.19 |
Enoletna sprememba* | 39.71% |
Dnevni razpon* | 334.61 - 340.19 |
Razpon 52 wk | 231.87-384.44 |
Povprečni obseg (10 dni) | 3.98M |
Povprečni obseg (3 meseci) | 59.59M |
Tržna kapitalizacija | 322.19B |
Razmerje P/E | 49.13 |
Število delnic v obtoku | 950.18M |
Prihodki | 28.54B |
EPS | 6.90 |
Dividenda (donosnost v %) | 1.33302 |
Beta | 0.33 |
Datum naslednjega zaslužka | Apr 27, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 337.93 | 5.58 | 1.68% | 332.35 | 342.09 | 328.30 |
Feb 2, 2023 | 330.39 | -2.41 | -0.72% | 332.80 | 334.80 | 316.14 |
Feb 1, 2023 | 342.15 | 1.23 | 0.36% | 340.92 | 345.40 | 336.80 |
Jan 31, 2023 | 343.91 | 5.17 | 1.53% | 338.74 | 344.11 | 338.74 |
Jan 30, 2023 | 340.18 | -1.86 | -0.54% | 342.04 | 347.28 | 339.15 |
Jan 27, 2023 | 341.77 | -2.99 | -0.87% | 344.76 | 347.70 | 341.32 |
Jan 26, 2023 | 347.65 | -2.14 | -0.61% | 349.79 | 351.79 | 346.30 |
Jan 25, 2023 | 349.26 | 7.35 | 2.15% | 341.91 | 349.50 | 341.91 |
Jan 24, 2023 | 345.92 | -16.82 | -4.64% | 362.74 | 364.89 | 339.80 |
Jan 23, 2023 | 341.82 | -2.04 | -0.59% | 343.86 | 345.86 | 339.80 |
Jan 20, 2023 | 345.80 | 1.01 | 0.29% | 344.79 | 348.73 | 341.12 |
Jan 19, 2023 | 350.82 | 1.39 | 0.40% | 349.43 | 355.30 | 349.43 |
Jan 18, 2023 | 351.45 | -4.05 | -1.14% | 355.50 | 358.73 | 351.25 |
Jan 17, 2023 | 357.38 | -1.09 | -0.30% | 358.47 | 361.50 | 356.17 |
Jan 13, 2023 | 361.23 | 6.08 | 1.71% | 355.15 | 362.95 | 355.15 |
Jan 12, 2023 | 358.72 | 3.25 | 0.91% | 355.47 | 360.15 | 351.69 |
Jan 11, 2023 | 359.86 | 7.67 | 2.18% | 352.19 | 361.49 | 348.71 |
Jan 10, 2023 | 352.54 | 5.75 | 1.66% | 346.79 | 352.96 | 342.22 |
Jan 9, 2023 | 349.45 | -13.34 | -3.68% | 362.79 | 364.60 | 348.43 |
Jan 6, 2023 | 362.71 | 4.92 | 1.38% | 357.79 | 366.20 | 356.41 |
Eli Lilly & Co Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Letni
- Četrtletno
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Skupni prihodki | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Prihodki | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Celotni stroški prihodkov | 5654.9 | 4447.7 | 4681.7 | 4721.2 | 5483.3 | 7312.8 |
Bruto dobiček | 15567.2 | 15526.1 | 16811.6 | 17598.3 | 19056.5 | 21005.6 |
Celotni odhodki iz poslovanja | 17763.3 | 17970.5 | 17958.8 | 17287.9 | 18481.8 | 22366.5 |
Celotna prodaja/splošni/upravni stroški Odhodki | 6452 | 5982.4 | 5975.1 | 6213.8 | 6121.2 | 6431.6 |
Raziskave in razvoj | 5243.9 | 5096.2 | 5051.2 | 5595 | 6085.7 | 7025.9 |
Nenavadni odhodki (prihodki) | 412.5 | 2444.2 | 2250.8 | 757.9 | 791.6 | 1596.2 |
Prihodki iz poslovanja | 3458.8 | 2003.3 | 3534.5 | 5031.6 | 6058 | 5951.9 |
Prihodki (odhodki) od obresti, neto Neoperativni | -76.5 | -58.6 | -83.2 | -320.2 | -326.6 | -137.5 |
Drugo, neto | -8.3 | 360.1 | 228.8 | 554.5 | 1498.5 | 341.1 |
Čisti dobiček pred obdavčitvijo | 3374 | 2304.8 | 3680.1 | 5265.9 | 7229.9 | 6155.5 |
Čisti dobiček po davkih | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Čisti dobiček pred dodatnimi postavkami | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Čisti dobiček | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Popravljen čisti dobiček | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Popravljene ponderirane povprečne delnice | 1061.82 | 1052.02 | 1033.67 | 935.684 | 912.505 | 911.681 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | 2.5782 | 4.27139 | 3.21757 | 4.95669 | 6.78758 | 6.12243 |
Dividends per Share - Common Stock Primary Issue | 2.04 | 2.08 | 2.25 | 2.58 | 2.96 | 3.4 |
Popravljen normalizirani dobiček na enoto čistega dobička | 2.89874 | 6.15171 | 5.37021 | 5.70063 | 7.63447 | 7.79951 |
Skupaj izredne postavke | -4697.7 | -93.9 | 3680.5 | 0 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Skupni prihodki | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Prihodki | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Celotni stroški prihodkov | 1878.6 | 1953.2 | 1430.8 | 2050.2 | 2072.1 |
Bruto dobiček | 4927 | 4786.9 | 5342 | 5949.7 | 5737.9 |
Celotni odhodki iz poslovanja | 5650.3 | 5336.7 | 5296.8 | 6082.7 | 5405.7 |
Celotna prodaja/splošni/upravni stroški Odhodki | 1576 | 1685.7 | 1577.9 | 1592 | 1557.9 |
Raziskave in razvoj | 1684.8 | 1672.8 | 1708.9 | 1959.4 | 1610.1 |
Nenavadni odhodki (prihodki) | 510.9 | 25 | 579.2 | 481.1 | 165.6 |
Prihodki iz poslovanja | 1155.3 | 1403.4 | 1476 | 1917.2 | 2404.3 |
Prihodki (odhodki) od obresti, neto Neoperativni | 219.2 | 133.9 | -323.4 | -167.2 | -503.3 |
Drugo, neto | 101.9 | 56.6 | 92.7 | 89.9 | 152.6 |
Čisti dobiček pred obdavčitvijo | 1476.4 | 1593.9 | 1245.3 | 1839.9 | 2053.6 |
Čisti dobiček po davkih | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Čisti dobiček pred dodatnimi postavkami | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Čisti dobiček | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Popravljen čisti dobiček | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Popravljene ponderirane povprečne delnice | 912.4 | 910.4 | 910.8 | 911.624 | 906.4 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | 1.48542 | 1.52702 | 1.21882 | 1.89343 | 2.0994 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.85 | 0.85 | 0.98 |
Popravljen normalizirani dobiček na enoto čistega dobička | 2.02635 | 1.55448 | 1.80644 | 2.41408 | 2.28211 |
Skupaj izredne postavke | 0 |
- Letni
- Četrtletno
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 15101.4 | 19202.1 | 20549.6 | 13709.6 | 17462.1 | 18452.4 |
Denarna sredstva in kratkoročne naložbe | 6038.6 | 8034.1 | 7408.9 | 2438.5 | 3681.3 | 3908.6 |
Denarna sredstva in ustrezniki | 4582.1 | 6536.2 | 7320.7 | 2337.5 | 3657.1 | 3818.5 |
Kratkoročne naložbe | 1456.5 | 1497.9 | 88.2 | 101 | 24.2 | 90.1 |
Celotne terjatve, neto | 4766.3 | 5262.2 | 5776.8 | 5541.5 | 6929 | 8127.2 |
Accounts Receivable - Trade, Net | 4029.4 | 4546.3 | 5776.8 | 4547.3 | 5875.3 | 6672.8 |
Total Inventory | 3561.9 | 4458.3 | 3098.1 | 3190.7 | 3980.3 | 3886 |
Prepaid Expenses | 734.6 | 1447.5 | 2036.7 | 2538.9 | 2871.5 | 2530.6 |
Total Assets | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Property/Plant/Equipment, Total - Net | 8252.6 | 8826.5 | 7996.1 | 8405 | 8681.9 | 8985.1 |
Property/Plant/Equipment, Total - Gross | 16777.6 | 18091.1 | 16663 | 17566.6 | 18252.6 | 18961.8 |
Accumulated Depreciation, Total | -8525 | -9264.6 | -8666.9 | -9161.6 | -9570.7 | -9976.7 |
Goodwill, Net | 3972.7 | 4370.1 | 1366.6 | 3679.4 | 3766.5 | 3892 |
Intangibles, Net | 4357.9 | 4029.2 | 1068 | 6618 | 7450 | 7691.9 |
Long Term Investments | 5207.5 | 5678.8 | 2005.4 | 1962.4 | 2966.8 | 3212.6 |
Other Long Term Assets, Total | 1913.8 | 2874.3 | 10922.7 | 4911.7 | 6305.8 | 6572 |
Total Current Liabilities | 10986.6 | 14535.9 | 11888.1 | 11775.2 | 12481.6 | 15052.7 |
Accounts Payable | 1349.3 | 1410.7 | 1207.1 | 1405.3 | 1606.7 | 1670.6 |
Accrued Expenses | 896.9 | 997.9 | 955.6 | 915.5 | 997.2 | 958.1 |
Notes Payable/Short Term Debt | 1299.3 | 2696.8 | 498.9 | 1494.2 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 638.1 | 1009.8 | 603.3 | 5.1 | 8.7 | 1538.3 |
Other Current Liabilities, Total | 6803 | 8420.7 | 8623.2 | 7955.1 | 9869 | 10885.7 |
Total Liabilities | 24798.2 | 33388.8 | 34079.7 | 36679.2 | 40991.5 | 39826.8 |
Total Long Term Debt | 8367.8 | 9940.5 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Long Term Debt | 8358.8 | 9931.8 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Capital Lease Obligations | 9 | 8.7 | ||||
Minority Interest | 72.8 | 75.7 | 1080.4 | 92.2 | 183.6 | 175.6 |
Other Liabilities, Total | 5371 | 8836.7 | 10602.1 | 8806.4 | 9639.8 | 7518.4 |
Total Equity | 14007.7 | 11592.2 | 9828.7 | 2606.9 | 5641.6 | 8979.2 |
Common Stock | 688.5 | 687.9 | 661 | 598.8 | 598.2 | 596.3 |
Additional Paid-In Capital | 5640.6 | 5817.8 | 6583.6 | 6685.3 | 6778.5 | 6833.4 |
Retained Earnings (Accumulated Deficit) | 16046.3 | 13894.1 | 11395.9 | 4920.4 | 7830.2 | 8958.5 |
Treasury Stock - Common | -80.5 | -75.8 | -69.4 | -60.8 | -55.7 | -52.7 |
Unrealized Gain (Loss) | 224 | 113.5 | 4.9 | 14.8 | 3.7 | |
Other Equity, Total | -8511.2 | -8845.3 | -8742.4 | -9541.7 | -9524.4 | -7360 |
Total Liabilities & Shareholders’ Equity | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Total Common Shares Outstanding | 1100.88 | 1100.01 | 1057.64 | 957.526 | 956.59 | 953.653 |
Other Current Assets, Total | 2229.1 | 0 | ||||
Deferred Income Tax | 1312.7 | 2187.5 | 2099.9 | 1733.7 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 16604.5 | 17295.5 | 17808.3 | 18452.4 | 16964.7 |
Denarna sredstva in kratkoročne naložbe | 3051.4 | 3271.2 | 3825.3 | 3908.6 | 2568.3 |
Denarna sredstva in ustrezniki | 3002.4 | 3220 | 3788.2 | 3818.5 | 2459.2 |
Kratkoročne naložbe | 49 | 51.2 | 37.1 | 90.1 | 109.1 |
Celotne terjatve, neto | 6658.6 | 6902.8 | 7025 | 8127.2 | 7805.7 |
Accounts Receivable - Trade, Net | 5592.8 | 5829.4 | 5914.3 | 6672.8 | 6322.5 |
Total Inventory | 3660.8 | 3824.9 | 3907.4 | 3886 | 3893 |
Prepaid Expenses | 3233.7 | 3296.6 | 3050.6 | 2530.6 | 2697.7 |
Total Assets | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Property/Plant/Equipment, Total - Net | 8630.1 | 8855.5 | 8920.4 | 8985.1 | 9102.7 |
Property/Plant/Equipment, Total - Gross | 18273.5 | 18697.7 | 18883.2 | 18961.8 | 19241 |
Accumulated Depreciation, Total | -9643.4 | -9842.2 | -9962.8 | -9976.7 | -10138.3 |
Goodwill, Net | 3877.4 | 3884.2 | 3884.1 | 3892 | 3892 |
Intangibles, Net | 8087.8 | 7985.4 | 7887.7 | 7691.9 | 7482.4 |
Long Term Investments | 3232.4 | 3474.9 | 3350.5 | 3212.6 | 2727.3 |
Other Long Term Assets, Total | 6406.1 | 6313.5 | 6336 | 6572 | 6750.2 |
Total Current Liabilities | 11714.2 | 15093.2 | 13682 | 15052.7 | 13386 |
Accounts Payable | 1639.6 | 1597.8 | 1566.8 | 1670.6 | 1433.3 |
Accrued Expenses | 649.9 | 755.5 | 836.6 | 958.1 | 693.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.9 | 1778.5 | 1563 | 1538.3 | 1355.9 |
Other Current Liabilities, Total | 9419.8 | 10961.4 | 9715.6 | 10885.7 | 9903.7 |
Total Liabilities | 39939.6 | 41364.6 | 40430 | 39826.8 | 37588.5 |
Total Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Deferred Income Tax | 2200.6 | 1857.3 | 1632.5 | 1733.7 | 1286.1 |
Minority Interest | 200.6 | 219.1 | 197.1 | 175.6 | 131.2 |
Other Liabilities, Total | 9624.6 | 9458.4 | 9396 | 7518.4 | 7632.3 |
Total Equity | 6898.7 | 6444.4 | 7757 | 8979.2 | 9330.8 |
Common Stock | 599.7 | 598.1 | 598.2 | 596.3 | 594.1 |
Additional Paid-In Capital | 6579.2 | 6669.2 | 6758 | 6833.4 | 6656.3 |
Retained Earnings (Accumulated Deficit) | 9181.3 | 8530.1 | 9639.4 | 8958.5 | 9369.4 |
Treasury Stock - Common | -52.7 | -52.7 | -52.7 | -52.7 | -50.5 |
Unrealized Gain (Loss) | 4.5 | 9.1 | 6.8 | 3.7 | -18.1 |
Other Equity, Total | -9413.3 | -9309.4 | -9192.7 | -7360 | -7220.4 |
Total Liabilities & Shareholders’ Equity | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Total Common Shares Outstanding | 959.019 | 956.575 | 956.589 | 953.653 | 950.155 |
- Letni
- Četrtletno
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Čisti prihodki/začetna postavka | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Denarna sredstva iz poslovanja | 4851 | 5615.6 | 5524.5 | 4836.6 | 6499.6 | 7260.7 |
Denarna sredstva iz poslovanja | 1496.6 | 1567.3 | 1609 | 1232.6 | 1323.9 | 1547.6 |
Deferred Taxes | 439.5 | -787.9 | 326.8 | 62.4 | -134.5 | -802.3 |
Nedenarne postavke | 661.4 | 1835.4 | 2735.4 | -3089.6 | -136.1 | 1956.3 |
Cash Taxes Paid | 700.6 | 246.5 | 1101.5 | 1180.5 | 954.6 | 1598.8 |
Denarna sredstva Plačane obresti | 146.4 | 192.7 | 223.8 | 305.5 | 345.8 | 338 |
Spremembe v obratnem kapitalu | -484.1 | 3204.9 | -2378.7 | -1687.2 | -747.4 | -1022.6 |
Denarna sredstva pri naložbenju | -3139.1 | -3783.6 | 1906 | -8082.9 | -2258.9 | -2762.3 |
Kapitalski izdatki | -1092 | -2163.6 | -3018.2 | -1353.5 | -2029.1 | -1873.2 |
Celotne druge postavke denarnih tokov pri naložbenju | -2047.1 | -1620 | 4924.2 | -6729.4 | -229.8 | -889.1 |
Denarna sredstva pri financiranju | -559.8 | 142.6 | -5904.9 | -2324.5 | -3137.1 | -4131.3 |
Postavke denarnega toka pri financiranju | -300.8 | -364.4 | -372.8 | -200.1 | -241.6 | -295.9 |
Total Cash Dividends Paid | -2158.5 | -2192.1 | -2311.8 | -2409.8 | -2687.1 | -3086.8 |
Izdaja (odplačilo) delnic, neto | -600.1 | -299.8 | -2491 | -4400 | -500 | -1250 |
Izdaja (odplačilo) dolga, neto | 2499.6 | 2998.9 | -729.3 | 4685.4 | 291.6 | 501.4 |
Učinki deviznih tečajev | -236.4 | -20.5 | -63.6 | -89.9 | 216 | -205.7 |
Neto sprememba denarnih sredstev | 915.7 | 1954.1 | 1462 | -5660.7 | 1319.6 | 161.4 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1355.3 | 2745.5 | 3855.6 | 5581.7 | 1902.9 |
Cash From Operating Activities | 1697.4 | 3472.9 | 5104.2 | 7260.7 | 2499.2 |
Cash From Operating Activities | 350.3 | 719.6 | 1101.9 | 1547.6 | 435.7 |
Deferred Taxes | -119.1 | -413.8 | -709.8 | -802.3 | -506.6 |
Non-Cash Items | 213.7 | 303.2 | 1404.6 | 1956.3 | 712.7 |
Changes in Working Capital | -102.8 | 118.4 | -548.1 | -1022.6 | -45.5 |
Cash From Investing Activities | -1283.5 | -1766.8 | -2383.3 | -2762.3 | -1013.8 |
Capital Expenditures | -492.1 | -1023.4 | -1479 | -1873.2 | -857.2 |
Other Investing Cash Flow Items, Total | -791.4 | -743.4 | -904.3 | -889.1 | -156.6 |
Cash From Financing Activities | -1058.4 | -2141.6 | -2604.8 | -4131.3 | -2878.3 |
Financing Cash Flow Items | -279.9 | -294.8 | -295.3 | -295.9 | -282.4 |
Total Cash Dividends Paid | -774.8 | -1543.1 | -2313.5 | -3086.8 | -885.5 |
Issuance (Retirement) of Stock, Net | 0 | -500 | -500 | -1250 | -1500 |
Issuance (Retirement) of Debt, Net | -3.7 | 196.3 | 504 | 501.4 | -210.4 |
Foreign Exchange Effects | -10.2 | -1.6 | 15 | -205.7 | 33.6 |
Net Change in Cash | -654.7 | -437.1 | 131.1 | 161.4 | -1359.3 |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
Lilly Endowment, Inc. | Investment Advisor | 10.8347 | 102948810 | -210000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6008 | 72221213 | 994066 | 2022-09-30 | LOW |
PNC Wealth Management | Investment Advisor | 5.4451 | 51738161 | -44061 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2364 | 40253792 | 58949 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.5343 | 33582472 | 168444 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.3604 | 31929656 | 631015 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.0547 | 29024874 | 282228 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9486 | 28017155 | -421333 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.5054 | 23805927 | 3379269 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2989 | 21843288 | -1593968 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 1.8324 | 17410725 | 0 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6935 | 16091249 | 373938 | 2022-09-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.0592 | 10064742 | -293324 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.866 | 8228610 | 173535 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8435 | 8014500 | -246196 | 2021-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7439 | 7068030 | -132558 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6244 | 5933104 | -307204 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.5893 | 5599174 | 637189 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.5885 | 5591703 | -216451 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.5868 | 5576096 | -144521 | 2022-09-30 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com GroupBorzni posredniki
Aktivne stranke mesečno
Mesečni obseg naložb
Dvigi vsak mesec
Kalkulator trgovanja
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Eli Lilly Company profile
O družbi Eli Lilly & Co
Družba Eli Lilly and Company je podjetje za proizvodnjo zdravil. Podjetje se ukvarja z odkrivanjem, razvojem, proizvodnjo, trženjem in prodajo farmacevtskih izdelkov po vsem svetu. Njeni izdelki za sladkorno bolezen so Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta in Trulicity. Njeni onkološki izdelki so Alimta, Cyramza, Erbitux, Retevmo, Tyvyt in Verzenio. Med imunološkimi izdelki družbe sta Olumiant in Taltz. Med njenimi nevroznanstvenimi izdelki so Cymbalta, Emgality, Reyvow in Zyprexa. Druge terapije so Bamlanivimab, etesevimab, Cialis in Forteo. Družba proizvaja in distribuira svoje izdelke prek obratov v Združenih državah, vključno s Portorikom, in približno osmih drugih državah. Njeni izdelki se prodajajo v približno 120 državah. Njene hčerinske družbe so med drugim Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc. in Avid Radiopharmaceuticals, Inc.
Industry: | Pharmaceuticals (NEC) |
Lilly Corporate Ctr
Drop Code 1094
INDIANAPOLIS
INDIANA 46285-0001
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 485.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com